1 |
Agarwal MB, Malhotra H, Chakrabarti P, et al (2015). Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythaemia vera, and essential thrombocythemia. Indian J Med Paediatr Oncol, 36, 3-16.
DOI
|
2 |
Cervantes F, Passamonti F, Barosi G (2008). Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia, 22, 905-14.
DOI
|
3 |
Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, et al (2015). Clinical manifestations and risk factors for complications of Philadelphia chromosome-negative myeloproliferative neoplasms. Asian Pac J Cancer Prev, 16, 5013-8.
DOI
|
4 |
Hoffbrand AV, Moss PAH. The anti-leukaemic myeloproliferative neoplasms (2011). Essential haematology, 6th edition, 208.
|
5 |
Johansson P (2006). Epidemiology of the myeloproliferative disorders polycythaemia vera and essential thrombocythemia. Semin Thromb Hemost, 32, 171-3.
DOI
|
6 |
Khattak SA, Ahmed S, Anwar J, Bozdar M (2012). Frequency of Janus associated kinase 2 (V617F) mutation in patients of polycythemia vera. J Coll Physicians Surg Pak, 22, 80-3.
|
7 |
Ma X, Vanasse G, Cartmel B, Wang Y, Selinger HA (2008). Prevalence of polycythaemia vera and essential thrombocythemia. Am J Hematol, 83, 359-62.
DOI
|
8 |
Sag SO, Gorukmez O, Ture M, et al (2015). MMP2 gene-735 C/T and MMP9 gene -1562 C/T polymorphisms in JAK2V617F positive myeloproliferative disorders. Asian Pac J Cancer Prev, 16, 443-9.
DOI
|
9 |
Sazawal S, Bajaj J, Chikkara S, et al (2010). Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders. Indian J Med Re, 132, 423-7.
|
10 |
Sadiq MA, Ahmed S, Ali N (2013). Frequency of Janus associated kinase 2 (JAK2) mutation in patients of BCR-ABL negative myeloproliferative neoplasms. Applied Life Sciences, 2, 235-40.
|
11 |
Tefferi A, Rumi E, Finazzi G, et al (2013). Survival and prognosis among 1545 patients with contemporary polycythaemia vera: an international study. Leukemia, 27, 1874-81.
DOI
|
12 |
Tefferi A, Barbui T (2015). Polycythaemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol, 90, 162-73.
DOI
|
13 |
Thiele J, Kvasnicka HM, Orazi A, et al (2008) . Polycythaemia vera. In: Swerdlow HS, Campo E, Haris LN, et al. WHO Classification of Tumours of Haemopoietic aAnd Lymphoid Tissues. Lyon: IARC, 40.
|
14 |
Usman M, Bilwani F, Kakepoto GN, et al (2004). Polycythemia vera and idiopathic erythrocytosis: comparison of clinical and laboratory parameters. J Pak Med Assoc, 54, 249-51.
|
15 |
Zhang ZR, Duan YC (2014). Interferon apha 2b for treating patients with JAK2V617F positive polycythaemia vera and essential thrombocytosis. Asian Pac J Cancer Prev, 15, 1681-4.
DOI
|
16 |
Yang JJ, Chen H, Zheng XQ, et al (2015). Methylated alteration of SHP1 complements mutation of JAK2 tyrosine kinase in patients with myeloproliferative neoplasm. Asian Pac J Cancer Prev, 16, 2219-25.
DOI
|
17 |
Yonal-Hindilerden I, Daglar-Aday A, Akadam-Teker B, et al (2015). The burden of JAK2V617F mutated allele in Turkish patients with myeloproliferative neoplasms. J Clin Med Res, 7, 161-70.
DOI
|